AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$KMTS

Hanley Conor sold $144K of KMTS

Hanley Conor sold 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.25 ($0.14M total) on 2026-09-08.

Original reporting
SEC EDGAR · Hanley Conor
Published Sep 11, 2026, 12:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The transaction is modest and unlikely to move the stock significantly, but it provides transparency for investors.

02

Market read

Provides a fresh data point for investors monitoring insider activity; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Sep 10, 2026

Background

SEC Form 4 filings disclose insider transactions; this filing reports a director's sale of KMTS shares.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Director Conor Hanley sold 5,694 shares of KMTS for $143,778, reducing his holding to 6,272 shares.

Expected impact

Potential short-term price pressure of 0.5‑1% if market reacts.

Evidence & confidence

A $144K sale by a director is a routine liquidity event; not material enough to drive a large move.

Market effects

Sector

Minimal impact on the medical device sector; insider activity is typical.

Regional

No regional effect; company trades on US exchanges.

Global

Limited global relevance; only affects KMTS shareholders.

Counterpoint

What could challenge this read

The sale could be a strategic reallocation rather than a lack of confidence, suggesting no downside.

Key entities

  • Company
    KestrA Medical Technologies, Ltd.

    Medical device manufacturer listed on Nasdaq under ticker KMTS.

  • Insider
    Conor Hanley

    Director of KMTS who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min